Alan Wilson and Szeto Zajarias show that vascular complications of the trans-femoral path remain an important factor because of the high profile of the catheters used in TAVI and the appearance of smaller devices, as well as the experience of surgeons, will progressively reduce complication rates. Josep Rodes-Cabau commented about the negative impact a stroke...
RENAL DES: reduction of restenosis in patients with kidney failure
Coronary angioplasty in patients with kidney failure is associated with an increased occurrence of events. This study compared the efficacy of preventing clinical restenosis using an everolimus-eluting stent versus a conventional stent, both implanted in the same patient with lesions in more than one vessel and suffering from kidney failure. The primary endpoint was target...
PROTAVI-C: Embolic protection during TAVI
Percutaneous aortic valve replacement (TAVI) is a new treatment option for patients that are inoperable or present a high surgical risk. Some studies have shown that the stroke rate may be higher with TAVI than with medical treatment or surgical replacement. Embolic protection has been used successfully for the carotids, but there is not much...
PROMUS PREMIER: new everolimus-eluting stent
The study aims to evaluate clinical, angiographic and IVUS results of the new platinum chromium everolimus stent. The new design of the device has additional proximal connectors to enhance the longitudinal strength where distortion is more common. Included were 100 patients with de novo coronary lesions and a reference diameter of 2.5 to 4 mm...
DEMONSTR8: better endothelial coverage by OCT for the new DES
There is still concern about the safety of drug-eluting stents (DES) due to the possibility of late and very late thrombosis. Dual antiplatelet aggregation for a year is recommended for patients receiving DES. The objective of this study was to test the non-inferiority of a new drug-eluting stent in terms of endothelial coverage after 3...
Exclusive Interview with Dr. Henrique Ribeiro on his article: coronary obstruction after TAVI
Recentemente uma revisão e metanálise sobre obstrução coronária após o implante de TAVI foi publicada na revista JAAC. Este artigo foi motivo de uma aula no TCT 2013 ministrada pelo Dr. Henrique Ribeiro (autor principal deste estudo). Segue abaixo o resumo do estudo e a entrevista com o dr. Henrique: Obstrução coronária pós TAVI Fundamentos...
Results of a Multiple Imaging Method Evaluation of the Bioabsorbable Emerolimus-eluting Coronary Stent System (ABSORB)
Hector M. Garcia-Garcia 2012-08-08
PRAMI: Treating other lesions in addition to the culprit of an acute infarction reduces events.
In the context of an ST-segment elevation myocardial infarction, primary angioplasty to treat the culprit lesion improves the prognosis. The role of angioplasty in unrelated arteries is not well established. Between 2008 and 2013, 465 patients with myocardial infarction underwent primary angioplasty and were randomized to preventive (234 patients) vs non-preventive angioplasty (231 patients). The...
DECAAF: Pre ablation magnetic resonance in patients with atrial fibrillation is capable of detecting the degree of fibrosis and predicting the success of the procedure.
260 patients with atrial fibrillation were included who underwent nuclear magnetic resonance 30 days before ablation and 90 days following. The patients were classified into four groups according to the degree of fibrosis: stage 1 ( < 10% fibrosis), stage 2 ( > 10% and < 20% fibrosis), stage 3 (> 20% and < 30%...
TAO trial: Otamixaban without advantages as the only anticoagulant in acute coronary syndromes
Despite progress in antiplatelet, anticoagulant therapy and invasive strategy, patients with non-ST-segment elevation acute coronary syndrome present an elevated risk of events. There is no consensus on the use of a single anticoagulant which can be administered in the Coronary Unit and also at the time of coronary intervention. The anticoagulant direct factor Xa inhibitor,...